Lung Cancer Surgical Management During the Outbreak of Coronavirus Disease 2019

Cafarotti, Stefano; Patella, Miriam

doi:10.1016/j.jtho.2020.03.027

Cited by 15 publications

(19 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While no paper was identified using the above search strategy, a recommendation from the Lung Cancer Center of the Oncology Institute of Southern Switzerland was retrieved by an exploratory search [15]. Here, the risk of lung cancer progression (high for stage T4 any N and for N2 any T as well as for oligometastases) and the risk of COVID-19 infection (high if older than 70 years in combination with > 2 associated diseases or with immunosuppression) were classified and it was recommended to consider exclusive nonsurgical treatment in patients with both high risk of cancer progression and of COVID-19 infection.…”

Section: Lung Cancermentioning

confidence: 99%

Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups

Vordermark

2020

Radiat Oncol

View full text Add to dashboard Cite

To examine, if a shift in indications for radiotherapy is to be expected in the context of the COVID-19 pandemic, the database Pubmed was searched for multidisciplinary or surgical expert recommendations on the role of radiotherapy in modified treatment concepts. Increased use of radiotherapy or chemoradiation instead of surgical treatment was recommended for defined patient groups with head-and-neck cancer, lung cancer, cervix cancer, esophageal cancer and prostate cancer. Omission of radiotherapy was considered in elderly patients with low-risk breast cancer and in early-stage Hodgkin's lymphoma. Only adjustments to the timing of radiotherapy were discussed for sarcoma and rectal cancer. Emerging recommendations on multidisciplinary cancer treatment concepts during the COVID-19 pandemic indicate a shift in radiotherapy indications and a potentially increased demand for radiotherapy.

show abstract

Section: Lung Cancermentioning

confidence: 99%

Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups

Vordermark

2020

Radiat Oncol

View full text Add to dashboard Cite

show abstract

“…Several local, national, and international recommendations for the management of cancer patients have emerged during the COVID-19 pandemic [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 ]. For example, there have been suggestions that surveillance should be delivered remotely for patients who have completed cancer treatment.…”

Section: Resultsmentioning

confidence: 99%

A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic

Zaniboni

Ghidini

Grossi

et al. 2020

Cancers

View full text Add to dashboard Cite

The COVID-19 pandemic has inevitably caused those involved in cancer care to change clinical practice in order to minimize the risk of infection while maintaining cancer treatment as a priority. General advice during the pandemic suggests that most patients continue with ongoing therapies or planned surgeries, while follow-up visits may instead be delayed until the resolution of the outbreak. We conducted a literature search using PubMed to identify articles published in English language that reported on care recommendations for cancer patients during the COVID-19 pandemic from its inception up to 1st June 2020, using the terms “(cancer or tumor) AND (COVID 19)”. Articles were selected for relevance and split into five categories: (1) personal recommendations of single or multiple authors, (2) recommendations of single authoritative centers, (3) recommendations of panels of experts or of multiple regional comprehensive centers, (4) recommendations of multicenter cooperative groups, (5) official guidelines or recommendations of health authorities. Of the 97 included studies, 10 were personal recommendations of single or multiple independent authors, 16 were practice recommendations of single authoritative cancer centers, 35 were recommendations provided by panel of experts or of multiple regional comprehensive centers, 19 were cooperative group position papers, and finally, 17 were official guidelines statements. The COVID-19 pandemic is a global emergency, and has rapidly modified our clinical practice. Delaying unnecessary treatment, minimizing toxicity, and identifying care priorities for surgery, radiotherapy, and systemic therapies must be viewed as basic priorities in the COVID-19 era.

show abstract

“…However, the ESMO recommendations were not based on risk classi cations and recommended surgery be delayed in cases of early-stage NSCLC. On the other hand, Cafarotti [18] suggested using a surgical treatment for NSCLC stages I to IIa, when there was a low risk of infection. The latter treatment plan was nearly identical to the strategy we proposed.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of non-small cell lung cancer treatment strategies in a region of China with low-risk for COVID-19

Cheng

2020

Preprint

View full text Add to dashboard Cite

Purpose This study analyzed the morbidity and mortality associated with non-small cell lung cancer (NSCLC) and evaluated treatment strategies for it in a low-risk area of COVID-19 in China. Materials and methods: We selected patients admitted to Sichuan Science City Hospital from September 2019 to February 2020 and divided them into experimental and control groups. The treatment strategy was evaluated by patients’ prognosis. Results: 9,010 patients were hospitalized. The total morbidity was 0.699%, of which 0.504% was observed in the control group and 0.991% in the experimental group (P=0.024). The total mortality was 0.999/103, of which 0.630/103 was observed in the control group and 1.413/103 in the experimental group (P=0.322). Therapy discontinuation and cancer progression in the experimental group were significantly higher than the control group (P＜0.001, P=0.007). The treatment methods and prognosis were not significantly different for early-stage patients between the two groups. Late-stage patients in the experimental group experienced significantly lower percentages of non-surgical treatments (P＜0.001), higher percentages of discontinued therapies (P＜0.001), lower percentages for prognosis of wellness (P＜0.001), and higher percentages of cancer progression (P＜0.001) than the control group. Conclusion: NSCLC exhibited significantly higher morbidities during the COVID-19 pandemic. The mortality in the experimental group was slightly higher than the control group, while the difference in cancer progression was significant. It is feasible to perform surgery for early-stage NSCLC patients, and treatment should not be suspended for late-stage patients in regions with low-risk for COVID-19 infection.

show abstract

Lung Cancer Surgical Management During the Outbreak of Coronavirus Disease 2019

Cited by 15 publications

References 1 publication

Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups

Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups

A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic

Evaluation of non-small cell lung cancer treatment strategies in a region of China with low-risk for COVID-19

Contact Info

Product

Resources

About